Skip to main content
Erschienen in: CNS Drugs 7/2014

01.07.2014 | Current Opinion

Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions

verfasst von: Paul A. Kudlow, Roger S. McIntyre, Raymond W. Lam

Erschienen in: CNS Drugs | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Studies have found that up to two-thirds of patients with major depressive disorder (MDD) do not fully respond to the first antidepressant. While switching antidepressants is a common strategy for antidepressant non-responders, there is still a lack of consensus about the optimal timing of a switch. Many clinicians wait for 6–12 weeks before considering a switch. The objectives of this paper are to (1) review the evidence for positive and negative predictive value (NPV) of early improvement at 2–4 weeks to predict final antidepressant response; (2) review randomized controlled trials (RCTs) that examine early switching strategies; and (3) provide future research directions and clinical recommendations for timing of antidepressant switching. We conducted a literature search for English-language studies via PubMed and Google Scholar, from 1984 to May 2013, with the following terms: ‘antidepressants’, ‘MDD’, ‘time course’, ‘trajectory’, ‘early response’, ‘onset’, ‘delayed response’, ‘early improvement’, ‘predictors’, ‘switch’, ‘combination therapy’, and ‘augmentation’. Replicated evidence indicates that lack of early improvement (e.g. <20 % reduction in a depression scale score) at 2–4 weeks can be an accurate predictor to identify eventual non-responders. The NPVs suggest that only about one in five patients with lack of improvement at 4 weeks will have a response by 8 weeks. Three RCTs examined early switch strategies, but results are inconsistent and comparisons limited by methodological differences. Future studies should incorporate a standard consensus definition of early improvement, discern whether the effect of early switching is specific to certain types of antidepressants, and determine whether early switch is superior to other strategies such as augmentation or combination. Notwithstanding these limitations, there is reasonable evidence to recommend earlier assessment for improvement. If there is no indication of early improvement at 2–4 weeks after starting an antidepressant, and taking into account other patient and clinical factors, a change in management can be considered.
Literatur
1.
Zurück zum Zitat Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96.PubMedCrossRef Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96.PubMedCrossRef
2.
Zurück zum Zitat Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.PubMedCrossRef Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(Suppl E1):e04.PubMedCrossRef
3.
Zurück zum Zitat Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III: pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–43.PubMedCrossRef Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III: pharmacotherapy. J Affect Disord. 2009;117(Suppl 1):S26–43.PubMedCrossRef
4.
Zurück zum Zitat Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.PubMedCrossRef Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.PubMedCrossRef
5.
Zurück zum Zitat Pae CU, Wang SM, Lee SY, et al. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother. 2012;12(10):1185–8.PubMedCrossRef Pae CU, Wang SM, Lee SY, et al. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother. 2012;12(10):1185–8.PubMedCrossRef
6.
Zurück zum Zitat Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry. 1984;41(3):238–45.PubMedCrossRef Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment. What is an adequate trial? Arch Gen Psychiatry. 1984;41(3):238–45.PubMedCrossRef
7.
Zurück zum Zitat Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53(9):785–92.PubMedCrossRef Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch Gen Psychiatry. 1996;53(9):785–92.PubMedCrossRef
8.
Zurück zum Zitat Posternak MA, Baer L, Nierenberg AA, et al. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry. 2011;72(7):949–54.PubMedCrossRef Posternak MA, Baer L, Nierenberg AA, et al. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry. 2011;72(7):949–54.PubMedCrossRef
9.
Zurück zum Zitat Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734–40.PubMedCrossRef Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734–40.PubMedCrossRef
10.
Zurück zum Zitat Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S492–8.PubMedCrossRef Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S492–8.PubMedCrossRef
11.
Zurück zum Zitat Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57(12):782–8.PubMed Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57(12):782–8.PubMed
13.
Zurück zum Zitat Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.PubMedCrossRef Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.PubMedCrossRef
14.
Zurück zum Zitat Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152(10):1500–3.PubMed Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152(10):1500–3.PubMed
15.
Zurück zum Zitat Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull. 2009;42(1):94–107.PubMed Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull. 2009;42(1):94–107.PubMed
16.
Zurück zum Zitat Lin CH, Lane HY, Chen CC, et al. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187–93.PubMedCrossRef Lin CH, Lane HY, Chen CC, et al. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187–93.PubMedCrossRef
17.
Zurück zum Zitat Soares CN, Fayyad RS, Guico-Pabia CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):57–65.PubMedCrossRef Soares CN, Fayyad RS, Guico-Pabia CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):57–65.PubMedCrossRef
18.
Zurück zum Zitat Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344–53.PubMedCrossRef Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70(3):344–53.PubMedCrossRef
19.
Zurück zum Zitat Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011;72(11):1478–84.PubMedCrossRef Uher R, Mors O, Rietschel M, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry. 2011;72(11):1478–84.PubMedCrossRef
20.
Zurück zum Zitat Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–42.PubMedCrossRef Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–42.PubMedCrossRef
21.
Zurück zum Zitat Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–55.PubMedCrossRef Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–55.PubMedCrossRef
22.
Zurück zum Zitat Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704.PubMedCrossRef Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704.PubMedCrossRef
23.
Zurück zum Zitat Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8):1983–9.PubMedCrossRef Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(8):1983–9.PubMedCrossRef
24.
Zurück zum Zitat Bose A, Tsai J, Li D. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig. 2012;32(6):373–85.PubMedCrossRef Bose A, Tsai J, Li D. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig. 2012;32(6):373–85.PubMedCrossRef
25.
Zurück zum Zitat Romera I, Perez V, Menchon JM, et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol. 2012;32(4):479–86.PubMedCrossRef Romera I, Perez V, Menchon JM, et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol. 2012;32(4):479–86.PubMedCrossRef
26.
Zurück zum Zitat Romera I, Perez V, Menchon JM, et al. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord. 2012;143(1–3):47–55.PubMedCrossRef Romera I, Perez V, Menchon JM, et al. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord. 2012;143(1–3):47–55.PubMedCrossRef
27.
Zurück zum Zitat Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70–83.PubMedCrossRef Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70–83.PubMedCrossRef
28.
Zurück zum Zitat Rosso G, Rigardetto S, Bogetto F, et al. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord. 2012;136(1–2):172–6.PubMedCrossRef Rosso G, Rigardetto S, Bogetto F, et al. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disord. 2012;136(1–2):172–6.PubMedCrossRef
29.
Zurück zum Zitat Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195(2):102–8.PubMedCrossRef Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry. 2009;195(2):102–8.PubMedCrossRef
30.
Zurück zum Zitat Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.PubMedCrossRef Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–83.PubMedCrossRef
31.
Zurück zum Zitat Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(Suppl 1):S9–13.PubMedCrossRef Lam RW, Filteau MJ, Milev R. Clinical effectiveness: the importance of psychosocial functioning outcomes. J Affect Disord. 2011;132(Suppl 1):S9–13.PubMedCrossRef
32.
Zurück zum Zitat Ishak WW, Balayan K, Bresee C, et al. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res. 2013;22(3):585–96.PubMedCrossRef Ishak WW, Balayan K, Bresee C, et al. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res. 2013;22(3):585–96.PubMedCrossRef
33.
Zurück zum Zitat Kudlow PA, Cha DS, Lam RW, et al. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. Sleep Med. 2013;14(10):943–9.PubMedCrossRef Kudlow PA, Cha DS, Lam RW, et al. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. Sleep Med. 2013;14(10):943–9.PubMedCrossRef
34.
Zurück zum Zitat McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013;70(8):821–9.PubMedCrossRef McGrath CL, Kelley ME, Holtzheimer PE, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013;70(8):821–9.PubMedCrossRef
35.
Zurück zum Zitat Kennedy SH, Downar J, Evans KR, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976–89.PubMedCrossRef Kennedy SH, Downar J, Evans KR, et al. The Canadian Biomarker Integration Network in Depression (CAN-BIND): advances in response prediction. Curr Pharm Des. 2012;18(36):5976–89.PubMedCrossRef
36.
Zurück zum Zitat Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract. 2013;26(4):389–96.PubMedCrossRef Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract. 2013;26(4):389–96.PubMedCrossRef
37.
Zurück zum Zitat Berlin I, Lavergne F. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. Eur Psychiatry. 1998;13(3):138–42.PubMedCrossRef Berlin I, Lavergne F. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. Eur Psychiatry. 1998;13(3):138–42.PubMedCrossRef
38.
Zurück zum Zitat Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423–8.PubMedCrossRef Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423–8.PubMedCrossRef
39.
Zurück zum Zitat Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269–75.PubMedCrossRef Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269–75.PubMedCrossRef
40.
Zurück zum Zitat Henkel V, Seemuller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009;115(3):439–49.PubMedCrossRef Henkel V, Seemuller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009;115(3):439–49.PubMedCrossRef
41.
Zurück zum Zitat van Calker D, Zobel I, Dykierek P, et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord. 2009;114(1–3):243–53.PubMedCrossRef van Calker D, Zobel I, Dykierek P, et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord. 2009;114(1–3):243–53.PubMedCrossRef
42.
Zurück zum Zitat Kuk AY, Li J, Rush AJ. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. J Clin Psychiatry. 2010;71(11):1502–8.PubMedCrossRef Kuk AY, Li J, Rush AJ. Recursive subsetting to identify patients in the STAR*D: a method to enhance the accuracy of early prediction of treatment outcome and to inform personalized care. J Clin Psychiatry. 2010;71(11):1502–8.PubMedCrossRef
43.
Zurück zum Zitat Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–42.PubMedCrossRef Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–42.PubMedCrossRef
44.
Zurück zum Zitat Kim JM, Kim SY, Stewart R, et al. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord. 2011;129(1–3):183–90.PubMedCrossRef Kim JM, Kim SY, Stewart R, et al. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord. 2011;129(1–3):183–90.PubMedCrossRef
45.
Zurück zum Zitat Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–64.PubMedCrossRef Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555–64.PubMedCrossRef
46.
Zurück zum Zitat Bares M, Novak T, Kopecek M, et al. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur Psychiatry. 2012;27(7):522–7.PubMedCrossRef Bares M, Novak T, Kopecek M, et al. The early improvement of depressive symptoms as a potential predictor of response to antidepressants in depressive patients who failed to respond to previous antidepressant treatments. Analysis of naturalistic data. Eur Psychiatry. 2012;27(7):522–7.PubMedCrossRef
47.
Zurück zum Zitat Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry. 2014;53:54–61. Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry. 2014;53:54–61.
Metadaten
Titel
Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions
verfasst von
Paul A. Kudlow
Roger S. McIntyre
Raymond W. Lam
Publikationsdatum
01.07.2014
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 7/2014
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-014-0171-5

Weitere Artikel der Ausgabe 7/2014

CNS Drugs 7/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.